Open Day at the Lendava site of Lek, a Sandoz company

  • The Lendava site of Lek, a Sandoz company, has been continuously growing and developing for more than 30 years. In total, the site employs more than 330 associates; over 90% are coming from the local environment.
  • Sandoz is aware of the importance of the Lendava site; therefore it has invested more than 110 million Euros in the development and modernization of production capacities at the entire site over the last 10 years.
  • Lek, a Sandoz company, invested 2.9 million EUR in environmental protection last year, environment-related investment was implemented at all sites, including Lendava.
7. 10. 2015

Today, the Lendava site of Lek, a Sandoz company, opened its door to the local community. They presented two key areas of their business operation that take place at the site, i.e. the Production of Anti-infectives and the Lendava Packaging Center. Through the development of activities over recent years, the site has considerably strengthened and become an important part of Sandoz, one of the leading global generic pharmaceutical companies. In Lendava, the company has also been expanding environmental investment in order to further reduce the impact of its operations on the environment.

The Lendava site of Lek, a Sandoz company, has been continuously growing and developing for over 30 years. Under the umbrella of Lek, a Sandoz company, three units operate at the Lendava site: the Anti-infectives Production Unit, the Packaging Center and the Lendava Wastewater Treatment Plant. In total, the site employs more than 330 associates. More than 90% of the employees come from the local area. Lek, a Sandoz company, thus maintains the role as a major employer in the region where unemployment is otherwise an issue of great concern.

Sandoz is aware of the importance of the Lendava site; therefore it has invested more than 110 million Euros in the development and modernization of production capacities at the entire site over the last 10 years. One of the major investments, worth more than 24 million EUR, is the newly opened Lendava Packaging Center.

Strengthening of cooperation with the local community and environmental investment

The business of Lek, a Sandoz company, is based on a long-term strategy that includes social responsibility in all areas of operation; this includes also an active involvement in the local community. Lek, a Sandoz company, therefore supports various projects and organizations in Lendava as well as in the wider region. For a number of years they have been closely cooperating with teachers and children of the Bilingual Primary School II Lendava and carrying out various activities, primarily associated with adolescents and children with developmental disabilities. Among other things, they have organized a Natural Science Day for the students of the Bilingual Primary School II Lendava a number of times, participated in the organization of a national music show and helped organize the 15th Special Olympics for the Maribor-Pomurje region. As a supporter of the Little House of Experiments project, Lek, a Sandoz company, enabled the Bilingual Primary School II Lendava to be the first school to host a visit of this mobile house of experiments.

In September, Lek, a Sandoz company, opened together with the Red Noses regular visits of clown doctors to the paediatric department of the Murska Sobota General Hospital. In addition, Lek, a Sandoz company, supports also some other associations and institutions in the region, including the Zarja Society for helping people in distress, Ozara Slovenia – the national association for quality of life, the Pomurje Safe House, the Youth Council Lendava, the Bilingual Primary School Lendava, the Bilingual Secondary School, the Home for the Elderly Lendava and the Youth Care and Education Center Veržej.

Sandoz’ fundamental approach to caring about the environment is to prevent all kind of pollution. Environmental, health and safety risks that could impact the environment, the employees and local population are reduced to the lowest possible level. In the process of waste management, the volumes of waste raw materials have been gradually reduced or recycled and the waste re-utilized to the greatest possible extent. Unpleasant odours are reduced by biofiltration of air.

»We have improved several environment-related aspects of the manufacture of anti-infectives. By additional investment and modernization we have successfully reduced a specific use of the ground water for the purpose of cooling the industrial processes. We re-directed the outflow of the used cooling water from a small recipient into the Mura river and started to utilize the excess heat from incinerator’s waste gasses«, said Gizela Štampar, Head of Anti-infective Production at Lendava.

Lek, a Sandoz company, invested in total 2.9 million EUR for environment protection.

* * *

Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit

Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32